Even younger pediatric patients with solid tumors or short-limbed dwarfism will now have access to treatment after the FDA approved label expansions late Friday for drugs by Genentech and BioMarin.
California-based BioMarin said that the FDA had approved a supplemental NDA for its drug Voxzogo, expanding…
Click here to view original post
